Literature DB >> 8533209

Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: impact of various modifiers.

B Hess1, U Meinhardt, L Zipperle, R Giovanoli, P Jaeger.   

Abstract

Rates of nucleation and aggregation of calcium oxalate crystals were derived from 20-min time course measurements of OD620 after mixing solutions containing CaCl2 and K2C2O4 at 37 degrees C, pH 5.7, ionic strength (IS) 0.21, with constant stirring (500 rpm); final assay concentrations were 4.25 mM calcium and 0.5 mM oxalate, respectively. The maximum increase of OD620 with time, termed SN, mainly reflects maximum rate of formation of new particles and thus crystal nucleation. After equilibrium has been reached, OD620 progressively decreases despite ionized calcium staying constant and no new particles being formed, due to crystal aggregation. Rate of aggregation, SA, is derived from the maximum decrease in OD620 with time. SN and SA are not independent, as indicated by a positive correlation (r = 0.844, P = 0.0001). Among the modifiers studied, citrate at 0.5-2.5 mM lowered both SN and SA in a concentration-dependent manner (P < 0.01 for all comparisons vs control). Chondroitin-6-sulfate at 6.25-25 mg/l moderately lowered SN, whereas it strongly inhibited aggregation (P < 0.01 vs control). At 6.8-20.4 mg/l, albumin did not affect nucleation, whereas it inhibited aggregation in a concentration-dependent manner (P < 0.005 vs control for all comparisons).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8533209     DOI: 10.1007/bf00393304

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  18 in total

Review 1.  Protein inhibitors of crystallization.

Authors:  F I Coe; J H Parks; Y Nakagawa
Journal:  Semin Nephrol       Date:  1991-03       Impact factor: 5.299

Review 2.  Physicochemical aspects of urolithiasis.

Authors:  B Finlayson
Journal:  Kidney Int       Date:  1978-05       Impact factor: 10.612

3.  Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein.

Authors:  E M Worcester; Y Nakagawa; C L Wabner; S Kumar; F L Coe
Journal:  Am J Physiol       Date:  1988-12

4.  Variations in the activity of urinary inhibitors in calcium oxalate urolithiasis.

Authors:  F Grases; C Genestar; P March; A Conte
Journal:  Br J Urol       Date:  1988-12

Review 5.  Physicochemical considerations in the development and prevention of calcium oxalate urolithiasis.

Authors:  D J Kok; S E Papapoulos
Journal:  Bone Miner       Date:  1993-01

6.  Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins.

Authors:  B Hess; Y Nakagawa; F L Coe
Journal:  Am J Physiol       Date:  1989-07

Review 7.  The role of Tamm-Horsfall glycoprotein and Nephrocalcin in calcium oxalate monohydrate crystallization processes.

Authors:  B Hess
Journal:  Scanning Microsc       Date:  1991-09

8.  A new approach to studying inhibitors of calcium oxalate crystal growth.

Authors:  C Hennequin; V Lalanne; M Daudon; B Lacour; T Drueke
Journal:  Urol Res       Date:  1993-03

9.  Effects of chondroitin sulphate, human serum albumin and Tamm-Horsfall mucoprotein on calcium oxalate crystallization in undiluted human urine.

Authors:  R L Ryall; R M Harnett; C M Hibberd; K A Edyvane; V R Marshall
Journal:  Urol Res       Date:  1991

10.  Modulation of calcium oxalate monohydrate crystallization kinetics in vitro.

Authors:  D J Kok; S E Papapoulos; L J Blomen; O L Bijvoet
Journal:  Kidney Int       Date:  1988-09       Impact factor: 10.612

View more
  20 in total

1.  Chinese herbal medicines and their efficacy in treating renal stones.

Authors:  Mayur Danny I Gohel; Siu Ping Wong
Journal:  Urol Res       Date:  2006-12

2.  Glycosylation of prothrombin fragment 1 governs calcium oxalate crystal nucleation and aggregation, but not crystal growth.

Authors:  Dawn Webber; Allen L Rodgers; Edward D Sturrock
Journal:  Urol Res       Date:  2007-11-07

3.  Antiurolithic effects of medicinal plants: results of in vivo studies in rat models of calcium oxalate nephrolithiasis-a systematic review.

Authors:  Aslam Khan; Samra Bashir; Saeed R Khan
Journal:  Urolithiasis       Date:  2021-01-23       Impact factor: 3.436

4.  In vitro crystallisation systems for the study of urinary stone formation.

Authors:  W Achilles
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 5.  Do "inhibitors of crystallisation" play any role in the prevention of kidney stones? A critique.

Authors:  William G Robertson
Journal:  Urolithiasis       Date:  2016-11-29       Impact factor: 3.436

6.  Potential thermodynamic and kinetic roles of phytate as an inhibitor of kidney stone formation: theoretical modelling and crystallization experiments.

Authors:  Saajidah Fakier; Allen Rodgers; Graham Jackson
Journal:  Urolithiasis       Date:  2019-02-14       Impact factor: 3.436

7.  Studies on the in vitro and in vivo antiurolithic activity of Holarrhena antidysenterica.

Authors:  Aslam Khan; Saeed R Khan; Anwar H Gilani
Journal:  Urol Res       Date:  2012-05-24

8.  Do teas rich in antioxidants reduce the physicochemical and peroxidative risk factors for calcium oxalate nephrolithiasis in humans? Pilot studies with Rooibos herbal tea and Japanese green tea.

Authors:  A Rodgers; M Mokoena; I Durbach; J Lazarus; S de Jager; H Ackermann; I Breytenbach; A Okada; M Usami; Y Hirose; R Ando; T Yasui; K Kohri
Journal:  Urolithiasis       Date:  2015-12-31       Impact factor: 3.436

9.  Inhibition of calcium oxalate crystallization by commercial human serum albumin and human urinary albumin isolated from two different race groups: evidence for possible molecular differences.

Authors:  Allen L Rodgers; Priscilla D Mensah; Sylva L Schwager; Edward D Sturrock
Journal:  Urol Res       Date:  2006-12

10.  Mass spectroscopic characteristics of low molecular weight proteins extracted from calcium oxalate stones: preliminary study.

Authors:  Wen-Chi Chen; Chien-Chen Lai; Chein-Cheng Lai; Yuhsin Tsai; Yu-Hsin Tsai; Wei-Yong Lin; Fuu-Jen Tsai
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.